FDA declines new import‑guidance for programmes

The Food and Drug Administration had a simple chance to clear up a messy corner of the drug market, and it passed. In a March 27, 2026 response to a citizen petition from the advocacy group Aimed Alliance, the agency said it would not issue a new guidance document on “alternative funding programs,” or AFPs, even though it agreed that drugs that bypass U.S. safeguards can be contaminated, counterfeit, or inconsistent in strength. The FDA’s reason was not that the issue is settled. It said writing the guidance was “not warranted at this time” and would not be an efficient use of limited resources (cnbc.com, aimedalliance.org). That matters because AFPs are not a theoretical problem. They are a fast-growing workaround inside employer health plans. These companies step in when a patient needs an expensive specialty drug, then steer that patient toward outside sources that are cheaper than the U.S. market. The pitch is savings. The mechanism is often much murkier. CNBC reported in November 2025 that some AFPs arranged overseas purchases and direct shipments to patients, while one company, PriceMDs, even flew a multiple-sclerosis patient to the Cayman Islands and the Bahamas to pick up Avonex in person (cnbc.com). The legal problem is not subtle. FDA rules already say that routine commercial importation of prescription drugs is generally barred unless it fits a narrow authorized pathway. Imported drugs must meet FDA standards for safety, effectiveness, labeling, manufacturing, and registration. At the border, the agency checks declared manufacturers, importers, product descriptions, and compliance codes. That system only works when the importer is operating inside the regulated channel. AFP models described by regulators and investigators often sit outside it, which is exactly why provenance becomes hard to prove after the fact (fda.gov, ecfr.gov). There is one major exception, and it shows why the FDA’s refusal to write AFP-specific guidance is so frustrating. Under Section 804 of the Food, Drug, and Cosmetic Act, states and tribes can propose tightly controlled importation programs for certain drugs from Canada. Those programs have a rulebook. They must show cost savings without adding risk to public health. They go through FDA review. They are limited, documented, and explicit about who is responsible for quality and oversight. Florida’s program was authorized under that framework, and the FDA still maintains a dedicated review process for similar proposals (fda.gov, fda.gov, ecfr.gov). AFPs are different in the precise ways that matter most. Aimed Alliance’s 2024 petition asked the FDA to spell out that distinction. It wanted the agency to say clearly whether third-party vendors working with employer plans can require patients to import drugs from abroad, whether those vendors can import on patients’ behalf, and how people should report violations. The petition argued that AFPs blur personal importation, state-run importation, and commercial middleman activity into one misleading package. The FDA denied the request, but it did not reject the underlying concern. It reaffirmed that supply-chain integrity is part of its public-health mission and that illegal importation can trigger serious penalties (aimedalliance.org, aimedalliance.org). That leaves everyone who has to interpret drug safety data in a worse position. Pharmacovigilance depends on knowing what product a patient actually received, where it was made, how it was stored, and whether the package in hand matches the approved one on paper. The Section 804 rule even builds adverse-event reporting into its definitions and oversight structure because those details are not optional. When a medicine arrives through an opaque foreign channel, the clinical question is no longer just what happened to the patient. It is whether the patient received the same drug at all (ecfr.gov, fda.gov). The deeper reason AFPs exist is plain enough. U.S. drug prices remain far above prices in Canada and other rich countries. KFF notes that one broad analysis found Canadian prices at 44 percent of U.S. levels, and per-capita spending on prescribed medicines was 42 percent higher in the United States than in Canada. That price gap keeps creating demand for shortcuts. The FDA just chose not to explain, in one focused document, where the legal shortcut ends and the unsafe one begins (kff.org).